Multi-Specific Monoclonal Antibodies – Global Clinical Trial Landscape - Focus On Asia Pacific

The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralize or promote its activity. Recently, technological advancements in the field have helped to improve the efficacy and safety of conventional immunoglobulin antibodies, making it possible to design and produce engineered antibodies that can mediate therapeutic functions previously not possible with conventional antibody formats.

Multi-specific monoclonal antibodies (Mab), specifically the bispecific types, are currently the most advanced therapeutic antibody drugs. Several approved drugs and many more are in active clinical development for a wide variety of cancers and other disease indications.¹ According to reports, Asia Pacific has been the fastest-growing region in multi-specific monoclonal antibody trials since 2018. The region contributes to over 40% of the global trials, relatively higher than that of the US and Europe.

Dive into the global clinical trial landscape of multi-specific Mabs, emphasizing trends in Asia Pacific, recent advancements in the field, and what researchers anticipate will significantly improve therapeutics for treating cancer and other unmet medical needs in this whitepaper.